enGene to Participate in Upcoming Investor Conferences

enGene Holdings Inc. (Nasdaq: ENGN) has announced its participation in several upcoming investor conferences, showcasing the company's commitment to engaging with investors and highlighting its advancements in genetic medicine. Management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 1:20 p.m. ET, followed by a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, at 8:00 a.m. ET. Additional fireside chats are scheduled for March 10 and 11, 2026, at the Barclays 28th Annual Global Healthcare Conference and the Citizens Life Sciences Conference, respectively.

A live webcast of these presentations will be available on enGene’s website under the "Events and Presentations" section and will be archived for 90 days, providing a valuable resource for investors who are unable to attend the live sessions.

enGene is a clinical-stage biotechnology firm focusing on non-viral genetic medicines aimed at delivering therapeutics to mucosal tissues to address diseases with significant clinical needs. Its lead program involves detalimogene voraplasmid, currently evaluated in the multi-cohort LEGEND Phase 2 trial for treating Non-Muscle Invasive Bladder Cancer (NMIBC). This condition poses a substantial clinical burden, and the trial includes pivotal evaluations for high-risk patients who have not responded to Bacillus Calmette-Guérin (BCG) therapy.

Developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, detalimogene allows for effective delivery of diverse molecular cargo, including DNA and RNA, enhancing therapeutic possibilities. For more information, visit enGene.com or connect through LinkedIn, X, and BlueSky.

As enGene Holdings Inc. (Nasdaq: ENGN) prepares for its participation in several key investor conferences in February and March 2026, this represents a critical opportunity for investors and analysts to reassess the company’s position in the biotech sector. enGene operates as a clinical-stage biotechnology firm focused on non-viral genetic medicines, particularly its lead program, detalimogene voraplasmid, which is currently under evaluation for Non-Muscle Invasive Bladder Cancer (NMIBC). The ongoing LEGEND Phase 2 trial is pivotal, assessing its efficacy in high-risk patients, a demographic marked by high unmet clinical needs.

Given the nature of the upcoming conference presentations and fireside chats, investors should closely monitor management's insights regarding trial progress, regulatory pathways, and potential commercialization strategies for detalimogene voraplasmid. Investors will likely be looking for any updates on enrollment numbers, anticipated timelines for trial results, and discussions on market potential, particularly due to the significant demand for effective treatments in the oncology space.

With enGene's innovative Dually Derivatized Oligochitosan (DDX) platform facilitating the delivery of genetic materials, it presents a compelling case for investment as novel therapies continue to gain traction. Given the rising interest in biotech stocks, particularly those engaged in genetic medicine, enGene’s advancements could be a highlight.

The upcoming conferences may influence stock volatility based on management's communications. Thus, it is prudent for investors to position themselves strategically ahead of these events. Keeping abreast of new developments from enGene, alongside industry trends, can yield valuable insights that help an investor maximize potential benefit while managing risk. Overall, participation in these conferences represents both an opportunity for enGene to enhance its visibility and for investors to gain critical knowledge about the company's trajectory.